However, further clinical trials indicated that Carlumab did not block the CCL-2/C–C chemokine receptor 2 (CCR-2) axis, nor did it show anti-tumor activity in metastatic castration-resistant prostate cancer. This evidence concerns the gene CCL2 and neoplasm.